Affordable Access

deepdyve-link
Publisher Website

Targeting cellular senescence as a new approach to chronic obstructive pulmonary disease therapy.

Authors
  • Barnes, Peter J1
  • 1 National Heart & Lung Institute, Imperial College, London, UK. Electronic address: [email protected]
Type
Published Article
Journal
Current opinion in pharmacology
Publication Date
Dec 13, 2020
Volume
56
Pages
68–73
Identifiers
DOI: 10.1016/j.coph.2020.11.004
PMID: 33326912
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Increasing evidence suggests that there is acceleration of normal lung ageing in chronic obstructive pulmonary disease (COPD), with the accumulation of senescent cells in the lung, which release an array of inflammatory proteins, which drive further senescence and disease progression. This suggests that drugs that target cellular senescence (senotherapies) may treat the underlying disease process in COPD and reduce disease progression and mortality. Several existing or future drugs may inhibit the development of cellular senescence, which is driven by chronic oxidative stress (senostatics), whereas other drugs selectively remove senescent cells (senolytics). Clinical studies of senotherapies have commenced in several age-related diseases, and these approaches appear to be safe and feasible, although no clinical studies in COPD patients have yet been reported. Copyright © 2020 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times